A Study of LY3537021 in Healthy Participants

Eli Lilly and Company47 enrolled

Overview

The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

LY3537021DRUG

Administered SC.

LiraglutideDRUG

Administered SC.

PlaceboDRUG

Administered SC.

Eligibility

Sex: ALLMin age: 21 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participants who are overtly healthy as determined through medical evaluation * Participants with body weight at least 55 kilograms (kg) and body mass index (BMI) of 23.0 to 40.0 kilograms per meter squared (kg/m²) * Males, or females who are not of childbearing potential. * Capable of giving signed informed consent form * Have blood pressure of less than 150/90 millimeters of mercury (mm Hg) and pulse rate of less than 100 beats per minute (bpm) (supine) Exclusion Criteria: * Have a significant history of current disorders capable of significantly altering the absorption, metabolism or elimination of drugs * History of malignancy within 5 years prior to screening * Have evidence of significant active psychiatric disorder(s) * Have undergone any form of bariatric surgery * Have an abnormality in the 12-lead electrocardiogram (ECG) * Are females who are lactating

Locations (1)

Lilly Centre for Clinical Pharmacology

Singapore, Singapore

Outcomes

Primary Outcomes

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

Time frame: Baseline up to Week 22

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.